Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against SelectQuote, Inc. due to allegations of misleading practices related to Medicare insurance plans, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by October 10, 2025 [4]. Group 1: Allegations Against SelectQuote - The complaint alleges that SelectQuote and its executives violated federal securities laws by making false and misleading statements, including directing Medicare beneficiaries to plans that compensated SelectQuote the most, regardless of quality [6]. - It is claimed that SelectQuote did not provide unbiased comparisons for Medicare Advantage plans and received illegal kickbacks to steer beneficiaries towards certain insurers [6]. - The U.S. Department of Justice filed a complaint stating that from 2016 to at least 2021, SelectQuote received tens of millions of dollars in illegal kickbacks, leading to materially false claims about offering unbiased coverage comparisons [7]. Group 2: Financial Impact - Following the DOJ's allegations, SelectQuote's stock price fell by $0.61, or 19.2%, closing at $2.56 per share on May 1, 2025, amid unusually heavy trading volume [7]. Group 3: Legal Proceedings - Investors who suffered losses exceeding $75,000 in SelectQuote between September 9, 2020, and May 1, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights [1]. - The role of lead plaintiff in the class action is open to any member of the putative class, with the ability to share in any recovery not affected by the decision to serve as lead plaintiff [8].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Sarepta between June 22, 2023 and June 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212- 983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Aug. 20, 2025 (GLOBE NEW ...

Group 1 - Halper Sadeh LLC is investigating iTeos Therapeutics, Inc. for potential violations related to its sale to Concentra Biosciences, LLC, which involves a cash offer of $10.047 per share and contingent value rights [1] - The contingent value rights include the right to receive 100% of iTeos' closing net cash exceeding $475 million and 80% of net proceeds from the sale of certain product candidates within six months post-closing [1] - WK Kellogg Co is being sold to The Ferrero Group for $23.00 per share in cash, prompting legal inquiries regarding shareholder rights [2] Group 2 - Halper Sadeh LLC may seek increased consideration for shareholders and additional disclosures regarding the proposed transactions [3] - Shareholders are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options at no charge [4] - The firm represents investors globally who have experienced securities fraud and corporate misconduct, recovering millions for defrauded investors [4]

Core Viewpoint - The Law Offices of Frank R. Cruz is investigating PubMatic, Inc. for potential violations of federal securities laws following a significant decline in its stock price after the release of its second quarter 2025 financial report [1][2]. Financial Performance - On August 11, 2025, PubMatic reported a headwind from a top Demand-Side Platform (DSP) buyer, which shifted clients to a new platform, leading to an expected significant revenue decline in the third quarter due to reduced ad spend from this partner [2]. - Following this announcement, PubMatic's stock price dropped by $2.23, or 21.1%, closing at $8.34 per share on August 12, 2025, resulting in financial injury to investors [2].

PHILADELPHIA, Aug. 19, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against CTO Realty Growth, Inc. (NYSE: CTO) ("CTO" or the "Company") on behalf of investors who purchased or otherwise acquired publicly traded securities of CTO between February 18, 2021 through June 24, 2025 (the "Class Period").Investor Deadline: Investors who purchased or acquired CTO securities during the Class Period may, no later than October 7, 2025, seek to be appointed as a ...

Core Viewpoint - Rosen Law Firm is reminding purchasers of common units of XPLR Infrastructure, LP about the lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company during the class period from September 27, 2023, to January 27, 2025 [1][5]. Group 1: Class Action Details - Investors who purchased XPLR common units during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by September 8, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen has been recognized as a Titan of Plaintiffs' Bar by Law360, highlighting the firm's expertise in this area [4]. Group 3: Allegations Against XPLR - The lawsuit alleges that XPLR made false and misleading statements regarding its operations as a yieldco, including struggles to maintain operations and the unsustainability of its business model [5]. - It is claimed that XPLR entered financing arrangements to temporarily alleviate operational issues while downplaying associated risks [5]. - The lawsuit asserts that XPLR's public statements were materially false and misleading, leading to investor damages when the true situation was revealed [5].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices involving Abacus Global Management, Inc. [1] Group 1: Investigation Details - The investigation is focused on whether Abacus and its officers or directors have engaged in fraudulent activities [1] - Investors are encouraged to contact Pomerantz LLP for more information regarding the investigation [1] Group 2: Allegations Against Abacus - A report by Morpheus Research claims that Abacus has manipulated its portfolio valuation methodology to present a misleadingly profitable image [3] - The report also criticizes Abacus's life expectancy estimation methods and highlights historical concerns regarding its co-founders [3] Group 3: Market Reaction - Following the release of the allegations, Abacus's stock price dropped by $1.64, or 21.47%, closing at $6.00 per share on June 5, 2025 [4]

Group 1 - Pomerantz LLP is investigating claims on behalf of Duolingo investors regarding potential securities fraud or unlawful business practices by the Company and its officers or directors [1] - JMP Securities has lowered its price target for Duolingo stock from $475 to $450 due to concerns about slowing user engagement, with daily active user growth decelerating to approximately 39% year-over-year in Q2 from about 51% in Q1 [3] - Following the news of the lowered price target, Duolingo's stock price fell by $23.60 per share, or 6.48%, closing at $340.49 per share on July 28, 2025 [3] Group 2 - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Molina Healthcare, Inc. and its officers or directors [1] Financial Performance - On July 7, 2025, Molina reported preliminary adjusted earnings of approximately $5.50 per share and lowered its full-year 2025 adjusted earnings guidance by over 10% to a range of $21.50 to $22.50 per share [3] - Following this announcement, Molina's stock price decreased by $6.97 per share, approximately 2.9%, closing at $232.61 per share [3] - On July 23, 2025, Molina released finalized second-quarter results, reporting adjusted earnings per diluted share of $5.48, which missed both analyst consensus estimates and prior company guidance [4] - The earnings shortfall was attributed to elevated medical cost pressures, including increased utilization of behavioral health, pharmacy, and inpatient/outpatient services [4] - Molina again lowered its full-year guidance due to updated information and revised assumptions regarding medical cost trends [4] - Following this news, Molina's stock price fell by $32.03 per share, approximately 16.8%, closing at $158.22 per share [5]

Core Viewpoint - A lawsuit has been filed against Centene Corporation and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Group 1: Company Overview - Centene Corporation is a healthcare company that provides services to consumers enrolled in government-sponsored healthcare programs such as Medicaid and Medicare, as well as those purchasing insurance under the Affordable Care Act [3]. Group 2: Financial Guidance and Performance - On December 12, 2024, Centene announced financial guidance for fiscal year 2025, claiming stability in earnings despite challenges [4]. - The company increased its 2025 guidance on February 4, 2025, citing enrollment overperformance, and again on April 25, 2025, due to strong growth in enrollment and retention [4]. - However, the actual market conditions showed lower than expected enrollment growth and increased morbidity rates in the majority of the states Centene serves [4]. Group 3: Stock Performance and Market Reaction - On July 1, 2025, Centene withdrew its previous guidance after an independent actuarial report revealed lower than expected market growth and higher morbidity rates [5]. - Following this news, Centene's stock price fell by $22.87 per share, a decline of over 40%, from $56.65 on July 1, 2025, to $33.78 on July 2, 2025 [5].